Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert K. Griffith is active.

Publication


Featured researches published by Robert K. Griffith.


The Journal of Clinical Pharmacology | 1993

The Hepatic First‐Pass Metabolism of Problematic Drugs

David Lalka; Robert K. Griffith; Carol L. Cronenberger

The first‐pass hepatic metabolism of a number of important therapeutic agents is inconsistent with traditional models that assume that the hepatic extraction ratio of a drug is constant in each individual (independent of the concentration of drug in the hepatic sinusoidal blood and also independent of the history of exposure to the drug). In this review, the authors examine the first‐pass metabolism of five “problematic drugs” (propranolol, lidocaine, propafenone, verapamil, and nitroglycerin). Each of these compounds has unique facets to its hepatic clearance and pharmacokinetics as well as striking similarities. Selected aspects of first‐pass metabolism are reviewed, and a theory that may explain some of the unusual behavior of the four lipophilic bases (propranolol, lidocaine, propafenone, and verapamil) is presented. Finally, the unusual and variable clearance of nitroglycerin is discussed.


Synthetic Communications | 1986

Improved Syntheses of Vinyl Imidazoles1

Robert K. Griffith; Richard A. Dipietro

Abstract A series of vinylimidazoles were synthesized via Wittig reactions on N-tritylimidazole-4-carboxaldehyde. Activated phosphonate ylids afforded yields in excess of 90% while the yields from unactivated ylids ranged from 10–82%. The trityl group may be removed by mild acid hydrolysis in high yield.


Bioorganic & Medicinal Chemistry Letters | 2002

Multisubstrate analogue inhibitors of glucosamine-6-phosphate synthase from Candida albicans.

Sridar V. Chittur; Robert K. Griffith

Compounds 1-6 were designed as multisubstrate inhibitors of glucosamine synthase. These compounds are also useful probes for measuring the distances between the two active sites in the multidomain protein. Our data suggest that the two binding pockets are in close proximity to each other.


Inflammation Research | 1985

Histamine receptor activation by unsaturated (allyl and propargyl) homologs of histamine

Jon W. Banning; Robert K. Griffith; Richard A. Dipietro

The spectrum of agonist activity for three new homologs of histamine (cis- and trans-imidazolylallylamine and imidazolylpropargylamine) was evaluated in the isolated guinea pig ileum and right atrium. The homologs were about three log units less potent than histamine in stimulating contractions of the longitudinal muscles of the ileum, but they were histamine-like, pharmacologically, because they were sensitive to blockade by pyrilamine and resistant to blockade by atropine. In the right atrium, these weak agonists were partially sensitive to blockade by cimetidine. The agonist activity of the cis-isomer in particular was completely blocked by a combination of cimetidine and propranolol, but resistant to reserpine treatment (neuronal catecholamine depletion). Therefore, these homologs of histamine have the ability to stimulate H1- and H2-histamine receptors andbeta-adrenoreceptorsin vitro.


Bioorganic & Medicinal Chemistry Letters | 1993

Synthesis of 4(5)-imidazolyl allylamines and propargylamines as inhibitors of diamine oxidase

Robert K. Griffith; Richard Anthony DiPietro

Abstract A series of four side-chain unsaturated histamine analogs were synthesized and evaluated as inhibitors of Diamine Oxidase, (DAO). All four target compounds were potent competitive inhibitors of DAO with Ki values ranging from 0.17 to 7.1 μM.


Burger's Medicinal Chemistry and Drug Discovery | 2003

Adrenergics and Adrenergic-Blocking Agents

Robert K. Griffith


Journal of Medicinal Chemistry | 1975

Radioprotective stereostructure-activity study of cis- and trans-2-mercaptocyclobutylamine analogs and homologs of 2-mercaptoethylamine

Ronald W. Hart; Ruth E. Gibson; J. Donald Chapman; Antoon P. Reuvers; Birandra K. Sinha; Robert K. Griffith; Donald T. Witiak


Annals of Pharmacotherapy | 2003

Enhancing Treatment of Bipolar Disorder Using the Patient's Belief System

Eugene H. Makela; Robert K. Griffith


Journal of Medicinal Chemistry | 1974

D-(R)- and L-(S)-3-Alkylaminopyrrolidino-substituted dihydrodibenzo[b,f]- and -[b,e]thiepins, xanthenes, and diphenylmethanes

Donald T. Witiak; Song Y. Hsu; James E. Ollmann; Robert K. Griffith; Shiv K. Seth; Michael C. Gerald


ChemInform | 1974

D-(R)- AND L-(S)-3-ALKYLAMINOPYRROLIDINO-SUBSTITUTED DIHYDRODIBENZO(B,F)- AND -(B,E)THIEPINS, XANTHENES, AND DIPHENYLMETHANES

Donald T. Witiak; S. Y. Hsu; James E. Ollmann; Robert K. Griffith; Shiv K. Seth; Michael C. Gerald

Collaboration


Dive into the Robert K. Griffith's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David Lalka

West Virginia University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge